title: Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?
abstract: OBJECTIVE
  The aim was to investigate indicators related to DNA damage and cancer pathogenesis in Type II diabetes cases with breast cancer. It was planned to evaluate the relationship between these markers with oral antidiabetic drugs.
  
  
  METHODS
  Fourty patients and 10 healthy individuals were included in the study. HIF-1α and 8-OHdG are examined in blood samples taken from these individuals with an ELISA Kit. Statistical analysis of data was performed with 95% confidence using Windows package program SPSS 15.0.
  
  
  RESULTS
  HIF-1α parameters were found to be meaningfully higher in the patient group than the controls in both pretreatment and posttreatment periods (p<0.05). No significant differences in terms of 8-OHdG between patients and controls. However, posttreatment serum HIF-1α ve 8-OHdG levels was found lower than pretreatment levels in patients receiving metformin, but not with pioglitazone. Conversely, serum 8-OHdG levels decreased significantly in these patients. When patients were evaluated according to the treatment groups (pioglitazone vs. metformin) no significant differences in terms of serum HIF-1? and 8-OHdG levels between treatment groups.
  
  
  CONCLUSIONS
  HIF-1α levels decreased significantly in the patient group receiving metformin. However, there was no significant difference in terms of HIF-1α levels in the patients receiving pioglitazone.
authors.affiliation: Department of Endocrinology and Metabolism Disease, Katip Celebi University, Izmir Ataturk Training and Research Hospital, Izmir, Turkey. ecarmu@gmail.com
authors.forename: Harman
authors.initials: H
authors.lastname: Ece
authors.forename: Erten
authors.initials: E
authors.lastname: Cigdem
authors.forename: Kucukzeybek
authors.initials: K
authors.lastname: Yuksel
authors.forename: Dirican
authors.initials: D
authors.lastname: Ahmet
authors.forename: Er
authors.initials: E
authors.lastname: Hakan
authors.forename: Tarhan Mustafa
authors.initials: TM
authors.lastname: Oktay
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D001943:Breast Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D016022:Case-Control Studies; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000097:blood*; D007328:Insulin / Q000378:metabolism; D008687:Metformin / Q000008:administration & dosage*; D000077205:Pioglitazone; D011379:Prognosis; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D000080242:8-Hydroxy-2'-Deoxyguanosine; D001786:Blood Glucose; D003849:Deoxyguanosine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007328:Insulin; D008687:Metformin; D000077205:Pioglitazone; D045162:Thiazolidinediones; C497442:HIF1A protein, human